Whats new
Whats new.
CLSA Equity Research - Tracking positively - FDA NSCLC Fast Track designation follows promising data readout (ASX:IMM) (Analyst: Andrew Paine)
October 4th 2022
For a copy of this analyst report please contact your CLSA advisor
Whats new
October 4th 2022
For a copy of this analyst report please contact your CLSA advisor